Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GenVec Reports Positive Interim Survival Data For TNFerade In Pancreatic Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Results presented at American Society of Clinical Oncology annual meeting show significant advantage in median survival versus standard care alone.

You may also be interested in...



Genvec May Partner TNFerade

Phase II/III pancreatic cancer trial goes on, but firm may need help to push indications such esophageal cancer.

Genvec May Partner TNFerade

Phase II/III pancreatic cancer trial goes on, but firm may need help to push indications such esophageal cancer.

GenVec Eyes BLA Submission for Pancreatic Cancer Therapy In 2008

FDA clears GenVec's Phase II/III trial for the gene-based oncologic TNFerade.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel